InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB vaccines, 2) new TB treatment combinations with existing medicines, 3) novel TB treatment opportunities with adjuvant combinations, and 4) tailored precision medicine approaches for the prevention and treatment of TB.
InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, is pleased to announce a strategic partnership with The Mueller Health Foundation (MHF), a private foundation dedicated to supporting innovative, accessible and affordable solutions to generate transformational treatment modalities and ultimately cures for lethal infectious diseases across the globe. The main focus for the Mueller Health Foundation has been primarily on the management of multidrug resistance (MDR), extensively drug-resistant (XDR), and programmatically incurable forms of tuberculosis (totally drug-resistant tuberculosis), which pose enormous challenges similar to those in the “pre-Antibiotics” era. The Mueller Health Foundation will partner with InveniAI to create a new high-value AI-driven machine learning platform called TBMeld® to identify and accelerate transformative solutions and vaccines for the management, treatment, and cure of TB. Additionally, the new platform will incorporate predictive modeling functionalities to estimate the effectiveness of TB drug compounds and compound combinations, as well as the effectiveness of new TB vaccines.
“Our mission at the Mueller Health Foundation (MHF) is to pioneer the use of precision medicine to be able to provide tailored, highly effective, and shorter treatment options for TB patients affected by both resistant and non-resistant strains of TB. We at MHF are also exploring novel ways of making existing TB vaccines more effective for all types of patients,” said Dr. Peter Mueller, Founder and President of the Mueller Health Foundation. He also states: “We are particularly excited to make use of machine learning algorithms and predictive modeling capabilities offered by InveniAI to find better approaches to preventing and treating tuberculosis faster and more effectively. What especially excites us is the opportunity to integrate this new platform, TBMeld®, into our own blockchain initiative TBConnect, which aims to create a global network of TB scientists, health care providers, NGOs, and government entities to foster the sharing and analysis of both research and public health information.”
“We are excited to create an AlphaMeld-powered platform that, together with complementary technologies such as blockchain and the crowdsourcing of knowledge, information, and experts around the world, will allow for the comprehensive collation of troves of data to expedite the discovery of novel solutions and vaccines to address this unmet need in TB resistant management. The predictive foresight enabled by the platform will allow us to focus on concepts that will have the highest probability of success,” said Krishnan Nandabalan, Ph.D. President and CEO, InveniAI LLC.